The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical efficacy, safety and immunological
changes of secukinumab(sec) compared to adalimumab(ada) in patients with active ankylosing
spondylitis(AS), who previously have an inadequate response to non-steroidal
anti-inflammatory drugs (NSAIDs) or bioagents.